Ecs Botanics (ASX:ECS) — Material Events

ASX:ECS · 15 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 13 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
13
ECS Botanics Secures German Distribution Deal with Nimbus HealthMedium
ECS Botanics Partners with Nimbus Health to Launch Medicinal Cannabis in Germany
11 Feb 2026 ·ASX Announcement ·85
ECS Botanics Returns to Profitability with Branded Growth and Infrastructure BoostMedium
ECS Botanics returns to profit and positive cash flow, driven by branded product growth and infrastructure expansion
27 Feb 2026 ·Half Year Financial Report ·85
ECS Botanics Accelerates B2C Growth Amid Record Harvest and Loan BoostMedium
ECS Botanics posts strong Q4 FY25 B2C growth, record harvest, and expands loan facility
28 July 2025 ·Quarterly Activity and Cash Flow Report ·80
ECS Botanics Turns Cash Flow Positive, Boosts B2C Revenue and Eyes EuropeMedium
ECS Botanics achieves positive cash flow, expands B2C revenue and European growth
14 Jan 2026 ·Quarterly Cash Flow and Operational Update ·80
ECS Botanics Sustains Cash Flow Amid Market Contraction and Expands International FootprintMedium
ECS Botanics reports third consecutive positive cash flow quarter, expands internationally, and grows B2C revenue 55%
28 Apr 2026 ·Quarterly Cash Flow and Operational Update ·80
ECS Botanics Hits Positive Cash Flow, Eyes European LaunchMedium
ECS Botanics Achieves Positive Cash Flow and Strong Revenue Growth with European Expansion Underway
7 Oct 2025 ·Quarterly Cash Flow and Operational Update ·80
New German GMP Rules Highlight ECS Botanics’ Manufacturing EdgeMedium
New German GMP Guidance Supports ECS Botanics' Integrated Manufacturing Strategy
3 July 2026 ·Regulatory Update ·80
ECS Botanics Surpasses 60% B2C Revenue with New Sugar-Free GummiesMedium
ECS Botanics B2C Sales Surpass 60% with Launch of Sugar-Free Gummies and New Distribution Partnership
21 Nov 2025 ·Business Update ·80
ECS Botanics Boosts B2C Sales and Harvest Amid Strategic ResetMedium
ECS Botanics posts FY25 revenue of $19.5M with strong B2C growth and record harvest despite non-cash impairments
29 Aug 2025 ·Financial Results ·75
ECS Botanics Poised for US Medicinal Cannabis Market Amid Regulatory ShiftsMedium
ECS Botanics Advances Preparations for US Medicinal Cannabis Market Entry
16 Dec 2025 ·ASX Announcement ·75
ECS Botanics Secures A$1.95M to Boost Global Reach and Product LineMedium
ECS Botanics raises A$1.95 million to fund international expansion and product development
13 Nov 2025 ·Capital Raising ·75
ECS Botanics Unveils AVANI AVA – Medicinal Cannabis Tailored for Women’s HealthMedium
ECS Botanics to Launch Women’s Health-Focused Medicinal Cannabis Brand AVANI AVA in January 2026
4 Dec 2025 ·Product Launch Announcement ·75
ECS Botanics Navigates $5.7M Loss with Bold B2C Shift and Asset Write-DownsMedium
ECS Botanics reports FY2025 $5.7M loss amid strategic B2C pivot and asset impairments, targets FY26 growth
29 Aug 2025 ·Annual Report ·Unexpected ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.